news Cellectis opens labs and offices in New York 9 April 2015 | By Victoria White Cellectis has established a new subsidiary, Cellectis, Inc. in New York City. The U.S. headquarters includes large state-of-the-art research laboratories...
article NGS In-Depth Focus 2015 9 April 2015 | By Caroline Richards, Editor, Drug Target Review In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
article Academic high-throughput screening; Opportunities for change 9 April 2015 | By Tim Hammonds (Deputy Director of Discovery: CRT Discovery Laboratories) Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...
article The impact of phenotypic and functional screening in CNS drug discovery 9 April 2015 | By Christine Williams (UCB), Wolfgang Fecke (UCB) Wolfgang Fecke and Christine Williams from UCB discuss the industry’s approach to drug discovery with costs escalating and output failing to achieve the corresponding increases in revenue...
article Label-free technologies for monitoring drug interactions 9 April 2015 | By Jean-Francois Masson (Universite de Montreal and Centre for Self-Assembled Chemical Structures), Kristy McKeating (Universite de Montreal) In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...
article Evaluation of a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening 9 April 2015 | By Anne-Pascale Luzy (Galderma R&D), Guy Bouvier (Galderma R&D), Jean-Michel Linget (Galderma R&D), Nicolas Orsini (Galderma R&D) This article evaluates a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening...
article The quest for accurate target validation 9 April 2015 | By Sheraz Gul (Fraunhofer-IME SP) Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
article The promise of induced pluripotent stem cells for liver disease, toxicology and drug discovery 9 April 2015 | By James Adjaye (Institute for Stem Cell Research and Regenerative Medicine), Nina Graffmann (Institute for Stem Cell Research and Regenerative Medicine), Peggy Matz (Institute for Stem Cell Research and Regenerative Medicine), Wasco Wruck (Institute for Stem Cell Research and Regenerative Medicine) We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
article Workshop Review: Cell-based Assays for Screening (December 2014) 9 April 2015 | By Sheraz Gul (Fraunhofer-IME SP) Sheraz Gul, Head of Biology at Fraunhofer-IME SP, provides an in-depth review of the Cell-Based Assays for Screening workshop which took place in December 2014...
news Nabriva Therapeutics announces financing to advance clinical development of new class of antibiotics 7 April 2015 | By Victoria White Nabriva, a biotechnology company focused on developing pleuromutilins, has announced the successful completion of a $120 million Series B financing...
news PhoreMost Ltd founded to identify new druggable targets for therapeutics 7 April 2015 | By Victoria White PhoreMost, a biopharmaceutical company focused on increasing diversity of novel therapeutics, has been founded to identify new druggable targets for cancer...
news PeptiDream announces license of Peptide Discovery Platform System (PDPS) technology to Novartis 2 April 2015 | By Victoria White PeptiDream Inc. has announced that Novartis has exercised its option to obtain a nonexclusive license to the Peptide Discovery Platform System technology...
news Merck Serono and Medicines for Malaria Venture sign agreement to develop potential antimalarial therapy 2 April 2015 | By Victoria White Merck Serono and MMV have announced that an agreement has been signed for Merck Serono to obtain the rights to the antimalarial compound DDD107498...
news Consortium signs deal with Basilea to develop resistance-busting cancer drugs 1 April 2015 | By Victoria White A consortium will collaborate with Basilea to progress a new family of cancer drugs designed to block several key cancer-causing proteins at once...
news Selvita initiates IND-enabling studies for its first-in-class PIM/FLT3 inhibitor 31 March 2015 | By Victoria White Selvita announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate...
